[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”4.16″ custom_padding=”0px|||||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_row admin_label=”row” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_padding=”||4px|||” global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||” theme_builder_area=”post_content”][et_pb_text admin_label=”Text” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” min_height=”280px” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n
Reviewed by Joost Boormans (Erasmus MC Cancer Institute, Rotterdam, the Netherlands)<\/em><\/p>\n <\/p>\n Data from a recent study support the use of a urinary methylation-based assay, i.e. Bladder EpiCheck\u00ae, to accurately identify recurrence in patients with high-grade non-muscle-invasive bladder cancer (NMIBC) treated with intravesical instillations [1]. [\/et_pb_text][et_pb_image src=”https:\/\/bcamonitor.org\/wp-content\/uploads\/2020\/09\/Table-TPS.png” align=”center” _builder_version=”4.16″ width=”50%” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_image][et_pb_image src=”https:\/\/bcamonitor.org\/wp-content\/uploads\/2020\/09\/Figure.png” align=”center” _builder_version=”4.16″ width=”70%” custom_margin=”||2px|||” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_image][et_pb_text _builder_version=”4.16″ text_font=”|600|||||||” text_text_color=”#18bfe4″ text_orientation=”center” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n Follow-up according to diagnostic categories for The Paris System for Reporting Urinary Cytology (TPS) (N=374 patients)<\/p>\n [\/et_pb_text][et_pb_text admin_label=”Text” _builder_version=”4.16″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||0px||false|false” custom_padding=”||0px|||” global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n Data from this study showed that a positive Bladder EpiCheck results significantly correlated with HGUC (odds ratio = 3.957 vs. SHGUC, p=0.003) and SHGUC (odds ratio = 3.791 vs. AUC, p=0.003). A negative Bladder EpiCheck result significantly correlated with NHGUC (odds ratio = 3.925, p=0.0003). When compared to pathology, Bladder EpiCheck demonstrated sensitivity of 95%, specificity of 85%, NPV of 97% and PPV of 76%. Sensitivity, specificity, negative and positive predictive value of Bladder EpiCheck were higher in HGUC vs SHGUC.<\/p>\n In conclusion, these data support that Bladder EpiCheck has high correlation with urine cytology in the diagnosis of SHGUC and HGUC<\/strong><\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_column type=”4_4″ _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”][et_pb_text _builder_version=”4.16″ global_colors_info=”{}” theme_builder_area=”post_content”]<\/p>\n References<\/strong><\/p>\n [\/et_pb_text][et_pb_button button_url=”https:\/\/bcamonitor.org\/slides-brochure\/” button_text=”Download the free slide resource and brochure” button_alignment=”center” _builder_version=”4.16″ custom_button=”on” button_text_color=”#ffffff” button_bg_color=”#3b8dbf” button_border_width=”0px” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.8.2″ _module_preset=”default” custom_padding=”2px||5px|||” global_module=”303″ saved_tabs=”all” global_colors_info=”{}” theme_builder_area=”post_content”][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Reviewed by Joost Boormans (Erasmus MC Cancer Institute, Rotterdam, the Netherlands) Data from a recent study support the use of a urinary methylation-based assay, i.e. Bladder EpiCheck\u00ae, to accurately identify recurrence in patients with high-grade non-muscle-invasive bladder cancer (NMIBC) treated with intravesical instillations [1]. The study retrospectively evaluated 374 patients with high-grade NMIBC, including […]<\/p>\n","protected":false},"author":0,"featured_media":166,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication"],"_links":{"self":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=319"}],"version-history":[{"count":1,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/319\/revisions"}],"predecessor-version":[{"id":392,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/posts\/319\/revisions\/392"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=\/wp\/v2\/media\/166"}],"wp:attachment":[{"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bcamonitor.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nThe study retrospectively evaluated 374 patients with high-grade NMIBC, including 106 patients with carcinoma in situ, under intravesical instillations (BCG or mitomycin C). The patients were followed up for 1 year by voided urinary cytology, followed by white-light cystoscopy and biopsies, where necessary. The referral for cystoscopy and biopsy was based on the cytology results according to The Paris System for Reporting Urinary Cytology (TPS) [2]: patients were referred for cystoscopy if falling in one of the following categories: high-grade urothelial carcinoma (HGUC), suspicious for high-grade urothelial carcinoma (SHGUC), or atypical urological cells (AUC). Bladder EpiCheck was performed together with cytology in all cases. An EpiCheck score \u226560 was considered positive.<\/p>\n\n